6-Mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes

Molecular Pharmacology

Volumn 51, Issue 3, 1997, Pages 414-421

  Hortelano, Sonsoles ^a   Boscá, Lisardo ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AMINOGUANIDINE; ANTIMETABOLITE; CD40 ANTIGEN; CYCLIC GMP; DNA; LINSIDOMINE; LIPOPOLYSACCHARIDE; MERCAPTOPURINE; MITOGENIC AGENT; MONOCLONAL ANTIBODY; NITRIC OXIDE; NITRIC OXIDE DONOR; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE ACTIVATION; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; SPLEEN CELL;

6-MERCAPTOPURINE; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SPLEEN;

EID: 0030937953     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Elion, G. B. The purine path to chemotherapy. Science (Washington D. C.) 244:41-47 (1989).
2. Reiter, A., M. Schrappe, W. D. Ludwig, W. Hiddemann, S. Sauter, G. Henze, M. Zimmermann, F. Lampert, W. Havers, and D. Niethammer. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133 (1994).
3. Riscoe, M. K., M. C. Brouns, and J. H. Fitchen. Purine metabolism as a target for leukemia chemotherapy. Blood Rev. 3:162-173 (1989).
4. Kaspers, G. J., L. A. Smets, R. Pieters, C. H. Van Zantwijk, E. R. Van Wering, and A. J. Veerman. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 85:751-756 (1995).
5. Bostrom, B., and G. Erdmann. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am. J. Pediatr. Hematol. Oncol. 15: 80-86 (1993).
6. Daly, A. K., S. Cholerton, W. Gregory, and J. R. Idle. Metabolic polymorphisms. Pharmacol. Ther. 57:129-160 (1993).
7. Lennard, L., H. A. Davies, and J. S. Lilleyman. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br. J. Cancer 68:186-190 (1993).
8. Hwang, I. Y., and A. A. Elfarra. Detection and mechanisms of formation of S-(6-purinyl) glutathione and 6-mercaptopurine in rats given 6-chloropurine. J. Pharmacol. Exp. Ther. 264:41-46 (1993).
9. Dayton, J. S., L. A. Turka, C. B. Thomson, and B. S. Mitchell. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol. Pharmacol. 41:671-676 (1992).
10. Reiter, Z., S. Thomson, O. N. Ozes, and N. W. Taylor. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation. Blood 81:1699-1708 (1993).
11. Robertson, L. E., S. Chubb, R. E. Meyn, M. Story, R. Ford, W. N. Hittelman, and W. Punkett. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 81:143-150 (1993).
12. Baixeras, E., L. Boscá, C. Stauber, A. Gonzalez, A. Carrera, J. A. Gonzalo, and C. Martínez-A. From apoptosis to autoimmunity: insights from the signaling pathways leading to proliferation or programmed cell death. Immunol. Rev. 142:53-91 (1994).
13. Cohen, J. J. Programmed cell death in the immune system. Adv. Immunol. 50:55-85 (1991).
14. Merino, R., L. Ding, D. J. Veis, S. J. Korsmeyer, and G. Nuñez. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J. 13:683-691 (1994).
15. Cuende, E., J. E. Alés-Martinez, L. Ding, M. Gonzalez-Garcia, C. Martínez-A, and G. Nuñez. Programmed cell death by bcl-2-dependent and independent mechanisms in B-lymphoma B cells. EMBO. J. 12:1555-1560 (1993).
16. H on chromosome 14 and near a transcriptional unit of 18. Cell 41:896-899 (1985).
17. McDonnell, T. J., N. Deane, F. M. Platt, G. Nuñez, U. Jaeger, J. P. McKearn, and S. J. Korsmeyer. Bcl-2-immunoglobulin transgenic mice demonstrates extended B cell survival and follicular lymphoproliferation. Cell 57:79-88 (1989).
18. Yin, X-M., Z. N. Oltval, and S. J. Korsmeyer. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (Lond.) 369:321-323 (1994).
19. Mannick, J. B., K. Asano, K. Izumi, E. Kieff, and S. J. Stamler. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79:1137-1146 (1994).
20. Genaro, A. M., S. Hortelano, A. Alvarez, C. Martínez-A., and L. Boscá. Nitric oxide rescues B cells from programmed cell death. J. Clin. Invest. 95:1884-1890 (1995).
21. Springer, T. Cell-surface differentiation in the mouse, in Monoclonal Antibodies (R. H. Kennett, T. J. McKearn, and K. B. Bechtol, eds.). Plenum Press, New York, 185 (1980).
22. Lyons, A. B., K. Samuel, A. Sanderson, and A. H. Maddy. Simultaneous analysis of immunophenotype and apoptosis of murine thymocytes by single laser flow cytometry. Cytometry 13:809-821 (1992).
23. Belloc, F., P. Dumain, M. R. Boisseau, C. Jalloustre, J. Reiffers, P. Bernard, and F. Lacombe. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 17:59-65 (1994).
24. Misko, T. P., R. J. Schilling, D. Salvemini, W. M. Moore, and M. G. Currie. A fluorometric assay for the measurement of nitrite in biological samples. Anal. Biochem. 214:11-16 (1993).
25. Chomczynski, P., and N. Sacchi. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159 (1987).
26. Stevens, C., N. Lempert, and B. M. Freed. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. Transplantation 51:1240-1244 (1991).
27. Saven, A., and L. D. Piro. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann. Intern. Med. 120:784-791 (1994).
28. Adamson P. C., F. M. Balis, M. E. Hawkins, R. F. Murphy, and D. G. Poplack. Desulfuration of 6-mercaptopurine: the basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells. Biochem. Pharmacol. 46:1627-1636 (1993).
29. Van Lonn, J. A., and R. M. Weinshilboum. Human lymphocyte thiopurine methyltransferase pharmacogenetics: effect of phenotype on 6-mercaptopurine-induced inhibition of mitogen stimulation. J. Pharmacol. Exp. Ther. 242:21-26 (1987).
30. Kelsoe, G., and B. Zheng. Sites of B-cell activation in vivo. Curr. Opinion Immunol. 5:418-422 (1993).
31. Gorczyca, W., J. Gong, B. Ardelt, F. Traganos, and Z. Darzynkiewicz. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:3186-3192 (1993).
32. Makrigiannis, A. P., J. Blay, and D. W. Hoskin. Cyclosporin A inhibits 2-chloroadenosine-induced DNA cleavage in mouse thymocytes. Int. J. Immunopharmacol. 16:995-1001 (1994).
33. Rothstein, T. L., J. K. M. Wang, D. J. Panka, L. C. Foote, Z. Wang, B. Stanger, H. Cui, S. T. Ju, and A. Marshak-Rothstein. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature (Lond.) 374:163-165 (1995).
34. Fulda, S., M. Honer, I. Menke-Moellers, and F. Berthold. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur. J. Cancer 31A:616-621 (1995).
35. Schena, M., L. G. Larsson, D. Gottardi, G. Gaidano, M. Carlsson, K. Nilsson, and F. Caligaris-Cappio. Growth and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79: 2981-2989 (1992).
36. Seth, P., R. Kumari, M. Dikshit, and R. C. Srimal. Modulation of rat peripheral polymorphonuclear leukocyte response by nitric oxide and arginine. Blood 84:2741-2748 (1994).
37. Trentin, L., R. Zambello, C. Agostini, F. Siviero, F. Adami, R. Marcolongo, R. Raimondi, T. Chisesi, G. Pizzolo, and G. Semenzato. Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood 81:752-758 (1993).